Dianthus Therapeutics DNTH EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Dianthus Therapeutics’s reported figures.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's EBITDA?
- Dianthus Therapeutics (DNTH) reported EBITDA of -$46.5M in Q1 2026.
- How has Dianthus Therapeutics's EBITDA changed year-over-year?
- Dianthus Therapeutics's EBITDA decreased by 40.3% year-over-year, from -$33.15M to -$46.5M.
- What is the long-term trend for Dianthus Therapeutics's EBITDA?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's EBITDA has grown at a 11.9% compound annual growth rate (CAGR), from -$72.67M to -$101.77M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.